Αποτελέσματα Αναζήτησης
The mean dose of procainamide was 1207 ± 487 mg/day. Procainamide therapy significantly decreased ICD interventions (median 5 [0–22.5] vs 15.5 [3–32.25], P < .05). Procainamide also decreased the total number of VT/VF episodes (median 5.5 [0.75–30] vs 19 [7.5–30], P < .05). Only 3 patients (8.8%) presented severe side effects (dyspnea ...
8 Μαΐ 2023 · Monitoring. Procainamide monitoring during therapy of an acute arrhythmia should involve monitoring QRS duration via cardiac monitoring, and the clinician should stop therapy QRS increases by 50% of its original width. Also, blood pressure requires frequent monitoring during treatment.
Procainamide was more effective by 1.5 hours in those with AF than AFL/both: 46.3% vs 22.2% (P<0.01). All predictors except dose were associated with higher adjusted odds of cardioversion by 1.5 hours (Table).
3 Σεπ 2024 · Loading dose: 15 mg/kg infused intravenously over 30 to 60 minutes; monitor ECG and blood pressure; stop the infusion if hypotension occurs or QRS complex widens by more than 50% of baseline. Renal Dose Adjustments. Oral: CrCl less than 10 mL/min: A dosing interval of every 8 to 24 hours is recommended.
For monomorphic ventricular tachycardia with a pulse or polymorphic ventricular tachycardia with a pulse (not due to torsades de pointes), administer procainamide at 1-2 grams over 5-60 minutes. See the dosage table above for further details.
20 Φεβ 2021 · Procainamide was administered within the scanner with intermittent intravenous boluses of 50 mg every minute until the complete suppression of PVCs up to a maximum dose of 10 mg/kg during continuous ECG monitoring and non-invasive blood pressure monitoring every minute.
We evaluated the efficacy of a single oral dose of procainamide to terminate paroxysmal tachycardia, when procainamide was taken shortly after onset of tachycardia, a regimen we have termed "periodic procainamide."
